A Phase 3 interventional study of Placebo and Nemolizumab in Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D. Completed at 174 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 4th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 941 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
17 studies in Dermatitis, Atopic by Galderma Group AG: 3 open now, 3 under way, 1 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 7th registered.
Galderma Group AG’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
Among Galderma Group AG’s 17 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
This was a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent subjects of age 12 years and above with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medication(s). Approximately 750 subjects were randomized in 2:1 to receive either nemolizumab or placebo, stratified by baseline disease severity (Investigator's Global Assessment (IGA) = 3, moderate; IGA = 4, severe) and peak pruritus numeric rating scale (PP NRS) severity (PP NRS >= 7; PP NRS \< 7). A minimum of 250 subjects were randomized in each PP NRS strata. All nemolizumab-treated subjects who were clinical responders at Week 16 (i.e., the end of initial treatment [Initial Treatment Period]/beginning of Maintenance Period) were re-randomized (1:1:1) to different treatment regimens (nemolizumab injections Q4W or every 8 weeks (Q8W) [with placebo injections at Weeks 20, 28, 36, and 44 to maintain the blind] or placebo Q4W). A clinical responder was defined as a subject at Week 16 with an IGA of 0 (clear) or 1 (almost clear) or a >= 75% improvement in EASI from baseline (EASI-75). All placebo-treated subjects who responded to placebo during the Initial Treatment Period continued to receive placebo Q4W in the Maintenance Period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Nemolizumab Active
Drug: Nemolizumab
Placebo
Nemolizumab
Also known as: CD14152
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population
IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.
Time frame: Week 16
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population
IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
Time frame: Week 16
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population
EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
Time frame: Week 16
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population
EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
Time frame: Week 16
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Time frame: Week 16
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Time frame: Week 16
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 16
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 16
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 16
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 16
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 4
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 4
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 4
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 4
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 2
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 2
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 1
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Time frame: Week 1
The study was conducted at 177 active sites in Australia, Austria, Canada, Czech Republic, Germany, Great Britain, Korea, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain and the United States from 27 June 2019 to 11 August 2022.
| Milestone | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W |
|---|---|---|---|---|---|---|
| Started | 321 | 620 | 0 | 0 | 0 | 0 |
| Safety population | 321 | 616 | 0 | 0 | 0 | 0 |
| Completed | 296 | 560 | 0 | 0 | 0 | 0 |
| Not completed | 25 | 60 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 9 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Subjects request | 11 | 25 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 3 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Physician/principal investigators decision | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 4 | 0 | 0 | 0 | 0 |
| Milestone | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 90 | 91 | 91 | 100 |
| Safety population | 0 | 0 | 91 | 90 | 91 | 100 |
| Completed | 0 | 0 | 76 | 79 | 69 | 82 |
| Not completed | 0 | 0 | 14 | 12 | 22 | 18 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 3 | 12 | 4 |
| Withdrew: Adverse event | 0 | 0 | 1 | 3 | 1 | 1 |
| Withdrew: Subjects request | 0 | 0 | 6 | 4 | 5 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Physician/pi decision | 0 | 0 | 2 | 1 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 1 |
IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population | 24.6 | 35.6 |
IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population | 21.4 | 35.5 |
EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population | 29.0 | 43.5 |
EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population | 23.8 | 41.6 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population | 17.8 | 42.7 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population | 18.6 | 46.1 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population | 11.2 | 30.6 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population | 7.6 | 27.8 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of subjects | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population | 19.9 | 37.9 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population | 22.4 | 42.1 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population | 6.5 | 27.4 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population | 7.1 | 28.3 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population | 3.7 | 16.0 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population | 2.9 | 12.6 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population | 3.1 | 17.7 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population | 3.8 | 20.7 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population | 1.2 | 4.5 |
The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
| percentage of participants | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg |
|---|---|---|
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population | 1.9 | 6.2 |
Collected over Initial Treatment Period: From baseline to Week 16 pre-dose; Maintenance Period: From end of Initial Treatment Period (i.e., Week 16) to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 0/321 (0%) | 4/321 (1.2%) | 67/321 (20.9%) |
| Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 0/616 (0%) | 6/616 (1%) | 144/616 (23.4%) |
| Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | 0/91 (0%) | 4/91 (4.4%) | 27/91 (29.7%) |
| Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | 0/90 (0%) | 3/90 (3.3%) | 28/90 (31.1%) |
| Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 0/91 (0%) | 2/91 (2.2%) | 33/91 (36.3%) |
| Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 0/100 (0%) | 1/100 (1%) | 35/100 (35%) |
| Event | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W |
|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/321 | 0/616 | 0/91 | 1/90 | 0/91 | 0/100 |
| Splenic injuryInjury, poisoning and procedural complications | 0/321 | 0/616 | 0/91 | 1/90 | 0/91 | 0/100 |
| AnxietyPsychiatric disorders | 0/321 | 0/616 | 0/91 | 1/90 | 0/91 | 0/100 |
| GoitreEndocrine disorders | 0/321 | 0/616 | 0/91 | 0/90 | 1/91 | 0/100 |
| AppendicitisInfections and infestations | 0/321 | 0/616 | 1/91 | 0/90 | 0/91 | 0/100 |
| COVID-19Infections and infestations | 0/321 | 0/616 | 1/91 | 0/90 | 0/91 | 0/100 |
| ErysipelasInfections and infestations | 0/321 | 0/616 | 0/91 | 0/90 | 1/91 | 0/100 |
| Dupuytren's contractureMusculoskeletal and connective tissue disorders | 0/321 | 0/616 | 1/91 | 0/90 | 0/91 | 0/100 |
| PeriarthiritisMusculoskeletal and connective tissue disorders | 0/321 | 0/616 | 1/91 | 0/90 | 0/91 | 0/100 |
| Plasmablastic lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/321 | 0/616 | 0/91 | 0/90 | 1/91 | 0/100 |
| Event | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W |
|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 33/321 | 73/616 | 7/91 | 8/90 | 12/91 | 10/100 |
| COVID-19Infections and infestations | 6/321 | 10/616 | 9/91 | 9/90 | 6/91 | 10/100 |
| Upper respiratory tract infectionInfections and infestations | 14/321 | 9/616 | 3/91 | 3/90 | 5/91 | 9/100 |
| NasopharyngitisInfections and infestations | 8/321 | 9/616 | 7/91 | 5/90 | 7/91 | 6/100 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 13/321 | 33/616 | 3/91 | 6/90 | 5/91 | 5/100 |
| HeadacheNervous system disorders | 11/321 | 28/616 | 5/91 | 5/90 | 3/91 | 1/100 |
The ITT population consisted of all randomized participants.
| Age, Continuous(years) | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Total |
|---|---|---|---|
| Mean | 33.3 ± 15.61 | 33.5 ± 15.92 | 33.3 ± 17.5 |
| Sex: Female, Male(Participants) | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Total |
|---|---|---|---|
| Female | 144 | 297 | 441 |
| Male | 177 | 323 | 500 |
| Ethnicity (NIH/OMB)(Participants) | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 64 | 96 |
| Not Hispanic or Latino | 288 | 552 | 840 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Race (NIH/OMB)(Participants) | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 51 | 117 | 168 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 18 | 36 | 54 |
| White | 244 | 451 | 695 |
| More than one race | 4 | 10 | 14 |
| Unknown or Not Reported | 1 | 3 | 4 |
Showing the first 100 of 174 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Dec 2021, 30 months.
Results were first posted in Aug 2024, 2 years 7 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 30 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab